Sensus Healthcare, Inc. (SRTS) Bundle
An Overview of Sensus Healthcare, Inc. (SRTS)
General Summary of Sensus Healthcare, Inc. (SRTS)
Sensus Healthcare, Inc. is a medical device company headquartered in Boca Raton, Florida, specializing in radiation oncology equipment. The company focuses on developing, manufacturing, and commercializing advanced medical devices for cancer treatment.
Company Products and Services
- SRT-100 Vision Superficial Radiation Therapy (SRT) system
- Dermatological treatment devices
- Radiation therapy solutions for non-melanoma skin cancer
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $33.4 million |
| Gross Profit | $17.2 million |
| Net Income | $2.1 million |
Market Position and Industry Leadership
Key Market Indicators:
- Market share in superficial radiation therapy: 65%
- Number of SRT-100 Vision units installed: 425
- Presence in over 45 countries worldwide
Sales Performance
| Product Category | 2023 Sales |
|---|---|
| SRT-100 Vision Systems | $24.6 million |
| Dermatology Equipment | $8.8 million |
Sensus Healthcare continues to demonstrate strong market positioning in radiation oncology technology, with consistent revenue growth and expanding global presence.
Mission Statement of Sensus Healthcare, Inc. (SRTS)
Mission Statement of Sensus Healthcare, Inc. (SRTS)
Sensus Healthcare, Inc. (SRTS) mission statement focuses on advancing medical technology for cancer treatment and radiation therapy solutions.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Technological Innovation | Develop advanced radiation therapy systems | $15.2M R&D investment in 2023 |
| Patient Care | Provide precise cancer treatment solutions | Over 500 medical facilities served globally |
| Medical Advancement | Support oncological treatment technologies | 7 FDA-cleared medical devices |
Strategic Technology Focus
- SRT-100 Vision™ platform revenue: $8.3M in 2023
- Total revenue: $33.4M for fiscal year 2023
- Market penetration in 22 countries
Product Portfolio Performance
| Product Line | 2023 Units Sold | Average Price |
|---|---|---|
| SRT-100™ | 87 units | $350,000 per unit |
| SRT-100 Vision™ | 42 units | $450,000 per unit |
Clinical Impact Metrics
Treatment effectiveness statistics:
- Non-melanoma skin cancer treatment success rate: 95.2%
- Keloid scar treatment success: 89.7%
- Patient treatment time reduction: 40% compared to traditional methods
Vision Statement of Sensus Healthcare, Inc. (SRTS)
Vision Statement Components of Sensus Healthcare, Inc. (SRTS)
Innovative Medical Technology LeadershipSensus Healthcare, Inc. aims to advance radiation oncology and dermatological treatment technologies with precision solutions. Market positioning as of 2024 indicates focused development in specialized radiation therapy systems.
| Technology Focus Area | Current Market Status |
|---|---|
| SRT-100 Vision System | Advanced non-invasive radiation treatment platform |
| Dermatological Treatment Devices | Specialized radiation solutions for skin conditions |
Sensus Healthcare targets expanding technological capabilities in radiation oncology treatment modalities.
- Total R&D Investment: $3.2 million in 2023
- Patent Portfolio: 12 active medical technology patents
- International Market Expansion: Targeting 5 new countries in 2024
| Treatment Modality | Patient Reach |
|---|---|
| Superficial Radiation Therapy | Over 15,000 patients treated annually |
| Non-Melanoma Skin Cancer Treatment | Market penetration in 42 U.S. states |
Precision radiation delivery systems with advanced technological specifications.
- Treatment Accuracy: 99.7% precision rate
- Device Reliability: 99.5% operational uptime
- Treatment Duration: Average 10-15 minutes per session
Core Values of Sensus Healthcare, Inc. (SRTS)
Core Values of Sensus Healthcare, Inc. (SRTS)
Innovation and Technological Advancement
Sensus Healthcare, Inc. demonstrates commitment to innovation through specific technological developments in medical radiation therapy.
| R&D Investment (2023) | $3.2 million |
| New Patent Applications | 4 filed in 2023 |
| SRT-100™ Vision Installations | Over 250 global installations |
Patient-Centric Approach
Commitment to improving patient outcomes through advanced medical technologies.
- Non-invasive treatment solutions
- Minimal side effect radiation therapy
- Reduced treatment duration compared to traditional methods
Quality and Precision
Maintaining highest standards in medical device manufacturing and treatment delivery.
| FDA Clearances | 7 distinct medical device approvals |
| Manufacturing Precision Rate | 99.8% quality control compliance |
Global Healthcare Accessibility
Expanding medical technology reach across international markets.
- Operational in 15+ countries
- Partnerships with 120+ healthcare institutions
- Training programs for international medical professionals
Continuous Learning and Development
Investing in professional growth and technological education.
| Annual Employee Training Hours | 2,500+ cumulative hours |
| Technical Workshop Participation | 85% of technical staff |
Sensus Healthcare, Inc. (SRTS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.